These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 7847399)
1. Submitting reports of adverse drug reactions to AJHP. Thompson CA Am J Hosp Pharm; 1994 Oct; 51(19):2358. PubMed ID: 7847399 [No Abstract] [Full Text] [Related]
2. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Wysowski DK; Swartz L Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284 [TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions, MedWatch reporting and medical student education. Lewis LD; Nierenberg DW Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):93-5. PubMed ID: 12642972 [No Abstract] [Full Text] [Related]
5. Monitoring for adverse drug events. Kennedy DL; Goldman SA Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003 [No Abstract] [Full Text] [Related]
6. Journals, FDA announce steps to encourage ADR reporting. Thompson CA Am J Hosp Pharm; 1994 Apr; 51(8):966-8, 974. PubMed ID: 8037224 [No Abstract] [Full Text] [Related]
7. Data incompatibility of adverse event reports electronically submitted to the AERS database. Glass LM Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):212-3. PubMed ID: 18236510 [No Abstract] [Full Text] [Related]
8. Criteria for journal reports of suspected drug reactions. Jones JK Clin Pharm; 1982; 1(6):554-5. PubMed ID: 7185544 [No Abstract] [Full Text] [Related]
9. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. de Vries TW; van Roon EN Arch Dis Child; 2010 Dec; 95(12):1023-6. PubMed ID: 20551194 [TBL] [Abstract][Full Text] [Related]
11. Strategy for surveillance of adverse drug events. Bright RA Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403 [No Abstract] [Full Text] [Related]
12. A history of adverse drug experiences: Congress had ample evidence to support restrictions on the promotion of prescription drugs. Waxman HA Food Drug Law J; 2003; 58(3):299-312. PubMed ID: 14626231 [No Abstract] [Full Text] [Related]
13. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics. Grandinetti CA; Osborne SF Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466 [No Abstract] [Full Text] [Related]
14. Recognizing and reporting adverse drug reactions. Lucas LM; Colley CA West J Med; 1992 Feb; 156(2):172-5. PubMed ID: 1536067 [TBL] [Abstract][Full Text] [Related]
15. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg. Woodcock J FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164 [No Abstract] [Full Text] [Related]
16. Beware of new drugs, study suggests. Levenson D Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085 [No Abstract] [Full Text] [Related]
17. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
18. Adverse drug reactions. O'Donnell J Leg Med; 1994; ():229-67. PubMed ID: 7830481 [TBL] [Abstract][Full Text] [Related]
19. Improving the quality of adverse drug reaction reporting by 4th-year medical students. Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973 [TBL] [Abstract][Full Text] [Related]
20. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007. Johann-Liang R; Wyeth J; Chen M; Cope JU Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]